Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ra Medical Systems, Inc. (RMED)

NEW YORK, NY / ACCESSWIRE / June 6, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ra Medical Systems, Inc. ("Ra Medical" or the "Company") (NYSE: RMED). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/rmed.

The investigation concerns whether Ra Medical and certain of its officers and/or directors have violated federal securities laws.

In September 2018, Ra Medical completed its initial public offering ("IPO"), issuing approximately 4.5 million shares of common stock priced at $17.00 per share. Then, on March 14, 2019, Ra Medical revealed that its fourth quarter 2018 financial results had been negatively impacted by issues related to the hiring and training of qualified sales personnel and certain production limitations. On this news, Ra Medical's stock price fell $2.14 per share, or roughly 32.6%, to close at $4.43 per share on March 15, 2019.

If you are aware of any facts relating to this investigation, or purchased Ra Medical shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/rmed. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC